Curis, Inc. Announces Resignation of Daniel R. Passeri as Director and Vice Chairman of the Board of Director, Effective from September 14, 2016
September 07, 2016 at 04:26 pm IST
Share
Curis, Inc. and Daniel R. Passeri entered into a letter agreement on September 2, 2016, which became effective on September 7, 2016 pursuant to which Mr. Passeri resigned as a director and Vice Chairman of the Board of Directors of the company. Mr. Passeri's resignation will become effective on September 14, 2016.
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). Its other clinical programs include Fimepinostat and CA-170. Fimepinostat is an oral, dual inhibitor of histone deacetylase (HDAC), and phosphotidyl-inositol 3 kinase (PI3K) enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target V-domain Ig Suppressor of T-cell Activation (VISTA) and PDL1 immune checkpoint proteins.
CURIS, INC. 
